Skip to contentR
Roivant Sciences Ltd.
R
ROIVRoivant Sciences Ltd. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.52M$2.52Mderived−66.7% vs Q4 2024 Net Income$302.99M$302.99MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Roivant Sciences Ltd. · CIK 1635088 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$415,240,000N/M Operating Cash Flowderived-$163,818,000N/M Free Cash Flowderived-$165,079,000N/M Margins · derivedOperating margin16477.8%+20242.2 pt vs Q4 2024
Net margin12023.6%+14751.1 pt vs Q4 2024
ended Mar 31, 2026 · filed May 20, 2026 · 50 d after period end